Innohep (Tinzaparin Sodium)

Tinzaparin sodium enhances the activity of antithrombin III, leading to selective inhibition of factor Xa and, to a lesser extent, factor IIa (thrombin). This action reduces thrombin generation, limits fibrin formation, and thereby prevents the growth and propagation of blood clots.

The dose of Innohep is individualized by the prescribing clinician based on the patient’s indication, weight, renal function, and overall risk profile. Healthcare professionals determine the appropriate amount and frequency according to current clinical guidelines.

Safety data for tinzaparin sodium in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the Innohep product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Innohep (tinzaparin) has a longer half‑life and a higher anti‑Xa to anti‑IIa activity ratio compared with some other LMWHs, which may allow once‑daily dosing in certain settings. Its safety and efficacy profile are comparable, but specific clinical decisions depend on patient characteristics and therapeutic goals.

Innohep should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution, as these actions can compromise product stability.

Innohep is supplied as a sterile injection solution for subcutaneous or intravenous administration. The injection is typically given into the abdominal wall or thigh using a sterile needle, following aseptic technique and the dosing instructions provided by the prescriber.

The most serious risks include major bleeding events such as intracranial or gastrointestinal hemorrhage, heparin‑induced thrombocytopenia (HIT), and rare allergic reactions that can be life‑threatening. Patients should be monitored closely for signs of bleeding or platelet count changes.

Innohep is contraindicated in patients with known hypersensitivity to tinzaparin or any heparin product, those with active major bleeding, and individuals who have a history of heparin‑induced thrombocytopenia. Caution is also advised for patients with severe renal impairment.